A Retrospective Assessment of the Initial Phase of Covid-19 and Its Implemented Treatment Strategies
Abstract
Coronaviridae is a typical type of viral family comprised of an exceptionally huge RNA genome with a characteristic appearance and a noteworthy propensity to move from creatures to people. Since the start of the 21st century, three exceptionally contagious and pathogenic coronaviruses have traversed the species boundary and caused lethal pneumonia, exacting serious episodes, and causing human wellbeing crises to an unfathomable extent. The COVID-19 pandemic, presumably, is the most wrecking one, over the most recent 100 years after Spanish influenza. To the quick assessment of the various methodologies for a capability to evoke defensive resistance and well-being to shorten undesirable resistant potentiation, which assumes a significant function in this virus's pathogenesis. Considering the forthcoming public health crisis, researchers around the globe are consolidating their logical scientific possessions and offering initial information in an unprecedented way. In this review, we have tried to summarize some of the SAR-nCoV2 treatments that essentially focus on the potential drugs including Lopinavir/Ritonavir, Favipiravir, Remdesivir, Chloroquine phosphate, Hydroxychloroquine, Arbidol, and so on. Other potential vaccine developments with their difficulties associated and their current status are also being addressed.
Keywords:
Keywords:
Coronaviridae, COVID-19 pandemic, Corona Virus, Potential antiviral drugs SARS-CoV-2, Vaccine against SARS-CoV-2DOI
https://doi.org/10.22270/jddt.v11i3-S.4868References
Taylor DR. Obstacles and advances in SARS vaccine development. Vaccine 2006; 24(7):863-71. https://doi.org/10.1016/j.vaccine.2005.08.102
Liu C, Zhou Q, Li Y, Garner L V, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci 2020; 6:315-31. https://doi.org/10.1021/acscentsci.0c00272
Rickie DO. The Lancet Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody. Lancet (London, England) 2020. https://doi.org/10.2139/ssrn.3546070
Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A review of sars-cov-2 and the ongoing clinical trials. Int J Mol Sci 2020; 21. https://doi.org/10.3390/ijms21072657
Who.int. 2021. COVID-19 Situation Reports. [online] Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports, Cited 12 April 2021.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl J Med 2020; 382:727-33.
https://doi.org/10.1056/NEJMoa2001017
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization, and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565-74. https://doi.org/10.1016/S0140-6736(20)30251-8
Wu Z, Yang L, Ren X, Zhang J, Yang F, Zhang S, et al. ORF8-related genetic evidence for Chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus. J Infect Dis 2016; 213:579-83. https://doi.org/10.1093/infdis/jiv476
Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in humans: a descriptive study. Chin Med J (Engl) 2020; 133: 1015-24. https://doi.org/10.1097/CM9.0000000000000722
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020; 94(7):1-9. https://doi.org/10.1128/JVI.00127-20
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun 2020; 109:102433. https://doi.org/10.1016/j.jaut.2020.102433
Nyayanit DA, Sarkale P, Baradkar S, Patil S, Yadav PD, Shete-Aich A, et al. Transcriptome & viral growth analysis of SARS-CoV-2-infected Vero CCL-81 cells. Indian J Med Res 2020; 152:70-6.
https://doi.org/10.4103/ijmr.IJMR_2257_20
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pacific J Allergy Immunol 2020; 38:1-9.
Chatterjee P, Nagi N, Agarwal A, Das B, Banerjee S, Sarkar S, et al. The 2019 novel coronavirus disease (COVID-19) pandemic: A review of the current evidence. Indian J Med Res 2020; 151:147-59. https://doi.org/10.4103/ijmr.IJMR_519_20
Phan LT, Nguyen TV, Luong QC, Nguyen HT, Le HQ, Nguyen TT, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020; 382:872-4.
https://doi.org/10.1056/NEJMc2001272
Go YY, Kim Y, Cheon S, Nam S, Ku B, Kim M, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5
Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of COVID-19 Patients. SSRN Electron J 2020; 1-25.
https://doi.org/10.2139/ssrn.3559601
Moujaess E, Kourie H, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Critical Rev Oncology/Hematology 2020; 150(10):29-32.
https://doi.org/10.1016/j.critrevonc.2020.102972
Abd El-Aziz T, Stockand J. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) an update on the status. Infection, Genetics, and Evolution 2020; 83:104327. https://doi.org/10.1016/j.meegid.2020.104327
Martina BEE, Haagmans BL, Kuiken T, Fouchier RAM, Rimmelzwaan GF, Van Amerongen G, et al. SARS virus infection of cats and ferrets. Nature 2003; 425:915.
https://doi.org/10.1038/425915a
Zheng L, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem 2020; 205:112687.
https://doi.org/10.1016/j.ejmech.2020.112687
Marian AJ. Current State of Vaccine Development and Targeted Therapies for COVID-19: Impact of Basic Science Discoveries. Cardiovasc Pathol 2020; 50:107278.
https://doi.org/10.1016/j.carpath.2020.107278
Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020; 94:119-24. https://doi.org/10.1016/j.ijid.2020.03.071
Noorimotlagh Z, Karami C, Mirzaee SA, Kaffashian M, Mami S, Azizi M. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review. Int Immunopharmacol 2020; 86.
https://doi.org/10.1016/j.intimp.2020.106738
Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. E Bio Medicine 2020; 55:1-12. https://doi.org/10.1016/j.ebiom.2020.102743
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis, and diagnosis of COVID-19. J Pharm Anal 2020; 10(2):102-8. https://doi.org/10.1016/j.jpha.2020.03.001
Dawood AA. Mutated COVID-19 may foretell a great risk for mankind in the future. New Microbes New Infect 2020; 35:100673. https://doi.org/10.1016/j.nmni.2020.100673
Kuttiatt VS, Abraham PR, Menon RP, Vaidya PC, Rahi M. Coronavirus disease 2019 in children: clinical & epidemiological implications. Indian J Med Res 2020; 152:21-40. https://doi.org/10.4103/ijmr.IJMR_977_20
Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): A pandemic (epidemiology, pathogenesis, and potential therapeutics). New Microbes New Infect 2020; 35:100679.
https://doi.org/10.1016/j.nmni.2020.100679
Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 2017; 37: 5-18. https://doi.org/10.1111/liv.13212
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as a potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395:e30-1.
https://doi.org/10.1016/S0140-6736(20)30304-4
Spagnuolo V, Castagna A, Lazzarin A. Darunavir for the treatment of HIV infection. Expet Opin Pharmacother 2018; 19(10):1149-63. https://doi.org/10.1080/14656566.2018.1484901
Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J. Med. Virol 2020; 92:1549- 55. https://doi.org/10.1002/jmv.25781
Decaro N, Lorusso A. Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses. Vet Microbiol 2020; 244:108693. https://doi.org/10.1016/j.vetmic.2020.108693
Le TT, Andreadakis Z, Kumar A, Román RG, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19:305-6.
https://doi.org/10.1038/d41573-020-00073-5
Speiser DE, Bachmann MF. Covid-19: Mechanisms of vaccination and immunity. Vaccines 2020; 8(3):1-22.
https://doi.org/10.3390/vaccines8030404
Algaissi AA, Alharbi NK, Hassanain M, Hashem AM. Preparedness, and response to COVID-19 in Saudi Arabia: Building on MERS experience. J Infect Public Health 2020; 13(6):834-8. https://doi.org/10.1016/j.jiph.2020.04.016
Vennema H, de Groot RJ, Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, et al. Early death after feline infectious peritonitis virus challenges due to recombinant vaccinia virus immunization. J Virol 1990; 64:1407-9.
https://doi.org/10.1128/JVI.64.3.1407-1409.1990
Samrat SK, Tharappel AM, Li Z, Li H. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Res 2020; 288:198141.
https://doi.org/10.1016/j.virusres.2020.198141
Sheng WH, Ko WC, Huang YC, Hsueh PR. SARS-CoV-2 and COVID-19. J Microbiol Immunol Infect 2020; 53(3): 363-4.
https://doi.org/10.1016/j.jmii.2020.03.033
Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 2020; 368:1016-20.
https://doi.org/10.1126/science.abb7015
Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020; 583:830-3. https://doi.org/10.1038/s41586-020-2312-y
Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Munnink BBO, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 2020; 368:1012-5. https://doi.org/10.1126/science.abb7314
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6:315-31. https://doi.org/10.1021/acscentsci.0c00272
Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J Biol Sci 2020; 27(10):2531-8.
https://doi.org/10.1016/j.sjbs.2020.04.033
Tirado S, Yoon K. Antibody-Dependent Enhancement of Virus Infection and Disease. Viral Immunology 2003; 16(1):69-86.
https://doi.org/10.1089/088282403763635465
Acosta PL, Caballero MT, Polack FP. Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol 2016; 23(3):189-95.
https://doi.org/10.1128/CVI.00609-15
Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients Recovered from COVID-19. J Am Med Assoc 2020; 323:1502-3. https://doi.org/10.1001/jama.2020.2783
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 2020; 27:325-8. https://doi.org/10.1016/j.chom.2020.02.001
Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med 2020; 18:1-9. https://doi.org/10.1186/s12967-020-02344-6
Peeples L. Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc Natl Acad Sci 2020; 117:8218-21. https://doi.org/10.1073/pnas.2005456117
Belete TM. A review of promising vaccine development progress for COVID-19 disease. Vacunas, 2020.
https://doi.org/10.1016/j.vacune.2020.10.009
Texas A&M University. BCG vaccine for health care workers as a defence against COVID-19 (BADAS). 2021 Available from https://clinicaltrials.gov/ct2/show/NCT04348370, Cited 12 April 2021.
NIH, U.S National Library of Medicine. Clinical Trials.gov. 2021 Available at https://clinicaltrials.gov/ct2/results?cond=Covid+vaccine, Cited 12 April 2021.
Published
Abstract Display: 1172 
PDF Downloads: 828 PDF Downloads: 82 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.